top of page

LET SCIENCE DO THE TALKING

 

We are a small molecule drug discovery and development biotech that uses a target-centric approach and classical medicinal chemistry to create new medicines

Metastatic melanoma cells

Photo by National Cancer Institute

 
CURADEV IN THE NEWS

Curadev Announces First Treatment Cycle Completion for the First Patient Dosed in a Phase 1 a/b Clinical Trial of its Allosteric STING Agonist CRD3874-SI in Patients with Advanced Cancer at Memorial Sloan Kettering Cancer Center in New York

Mountains

ABOUT
US

Curadev is a clinical stage biotech company, dedicated to discovering and developing novel small molecule therapeutics for the treatment of intractable diseases. Utilizing a target-centric approach, innovative screening schemes and traditional wet-lab chemistry and pharmacology, Curadev has built an impressive portfolio of discovery research programs, resulting in patent-protected drug candidates that modulate next-generation drug targets.

About us
bottom of page